PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held company developing therapies based on interleukin 12 (IL-12) as a radiation medical countermeasure and as a hematopoietic immunotherapeutic (HIT), today announced that Neumedicines President & CEO Lena A. Basile, Ph.D., J.D., will present at the Biotech Showcase™ conference on Wednesday, January 15, at 11:30 a.m. The conference is being held at the Parc 55 Wyndham hotel in San Francisco.
During the Neumedicines presentation, Dr. Basile will discuss results from a blinded, randomized study showing that a single, low-dose of HemaMax™ (recombinant human interleukin 12 or rHuIL-12) administered subcutaneously to non-human primates at 24-25 hours post exposure to lethal radiation significantly increased survival compared with control. In the same study, 18 consecutive days of treatment with Neupogen® (filgrastim or granulocyte colony-stimulating factor [G-CSF]) did not provide any survival benefit versus control.
“HemaMax™ is the only drug that has shown the ability to induce early bone marrow regeneration followed by the hematopoietic recovery of all blood cell lineages to support survival following exposure to lethal radiation without antibiotics, fluids or blood products,” said Dr. Basile. “We are delighted with the opportunity to discuss the results from our studies with the biotech and pharmaceutical executives attending this conference.”
Neumedicines is developing HemaMax™ for the treatment of hematopoietic syndrome of acute radiation sickness (HSARS) and for indications in oncology. G-CSF is an FDA-approved drug for use in cancer patients to stimulate the growth of neutrophils following chemotherapy. Although G-CSF is not approved by U.S. Food and Drug Administration (FDA) for the treatment of HSARS, according to the Centers for Disease Control and Prevention (CDC) and the Radiation Injury Treatment Network (RITN), G-CSF is the currently recommended emergency use treatment option for victims of a radiation disaster.
Biotech Showcase™, in its sixth year, features presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals. For more information and online registration please visit the conference website at www.ebdgroup.com/bts.
HemaMax™ is based on recombinant human interleukin-12 (IL-12). IL-12 is a heterodimeric cytokine that has been shown to play an essential role in regulating inflammatory responses, including innate resistance to infection and an ability to stimulate the production of interferon-gamma from natural killer cells, macrophages and T-cells. IL-12 also induces resistance to many pathogens and to transplantable and chemically induced tumors.
About Neumedicines Inc.
Neumedicines Inc. is developing interleukin-12 (IL-12), which addresses multiple indications including unmet clinical and societal needs in the fields of oncology, hematology and immunology. The company’s product candidate, HemaMax™ (rHuIL-12), functions by targeting multiple pathways of hematopoiesis and innate immunity. HemaMax™ is currently being developed as a biodefense radiation medical countermeasure and for indications in oncology, initially as a hematopoietic immunotherapeutic (HIT) in cancer patients receiving aggressive chemotherapy. Neumedicines is committed to developing and maximizing the scientific, clinical and commercial potential of its product pipeline. For more information, please visit www.neumedicines.com or follow the company on Twitter @Neumedicines.